✦ LIBER ✦

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Previously Treated Metastatic Breast Cancer

✍ Scribed by Dickler, M.N.

Book ID: 122062593
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 59 KB
Volume: 16
Category: Article
ISSN: 1043-321X
DOI: 10.1016/S1043-321X(05)80307-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Data with ZD6474, a Small-Molec

Phase II Data with ZD6474, a Small-Molecule Kinase Inhibitor of Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor, in Previously Treated Advanced Non–Small-Cell Lung Cancer

✍ David Lee; Ronald B. Natale; Eric Nadler; Vinay K. Jain 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 77 KB

A Phase II Safety and Efficacy Study of

A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer

✍ Pili, Roberto; Qin, Rui; Flynn, P.J.; Picus, Joel; Millward, Michael; Ho, Wing M 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 791 KB

A specific vascular endothelial growth f

A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the antiproliferative effect of trastuzumab in human epidermal growth factor receptor 2 overexpressing breast cancer cell lines

✍ Elizabeth M.H. Kim; Catherine Lobocki; Linda Dubay; Vijay K. Mittal 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 680 KB

Lapatinib: A small-molecule inhibitor of

Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer

✍ Amye J. Tevaarwerk; Jill M. Kolesar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 188 KB

Ocular findings in patients with solid t

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Phase I and II clinical trials

✍ Murray, P I; Bristow, E; Forsythe, B J; Faulkner, K; Tullo, A B; Esmaeli, B 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 187 KB

Phase II study of SU5416—a small-molecul

Phase II study of SU5416—a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor—in patients with refractory myeloproliferative diseases

✍ Francis J. Giles; Maureen A. Cooper; Lewis Silverman; Judith E. Karp; Jeffrey E. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

## Abstract ## BACKGROUND Increased bone marrow angiogenesis and vascular endothelial growth factor (VEGF) levels are of adverse prognostic significance in patients with myeloproliferative disorders (MPD), including agnogenic myeloid metaplasia (AMM), chronic myeloid leukemia in blastic phase (CML